Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 28;21(1):E44.
doi: 10.3390/molecules21010044.

Site-Selective Ribosylation of Fluorescent Nucleobase Analogs Using Purine-Nucleoside Phosphorylase as a Catalyst: Effects of Point Mutations

Affiliations

Site-Selective Ribosylation of Fluorescent Nucleobase Analogs Using Purine-Nucleoside Phosphorylase as a Catalyst: Effects of Point Mutations

Alicja Stachelska-Wierzchowska et al. Molecules. .

Abstract

Enzymatic ribosylation of fluorescent 8-azapurine derivatives, like 8-azaguanine and 2,6-diamino-8-azapurine, with purine-nucleoside phosphorylase (PNP) as a catalyst, leads to N9, N8, and N7-ribosides. The final proportion of the products may be modulated by point mutations in the enzyme active site. As an example, ribosylation of the latter substrate by wild-type calf PNP gives N7- and N8-ribosides, while the N243D mutant directs the ribosyl substitution at N9- and N7-positions. The same mutant allows synthesis of the fluorescent N7-β-d-ribosyl-8-azaguanine. The mutated form of the E. coli PNP, D204N, can be utilized to obtain non-typical ribosides of 8-azaadenine and 2,6-diamino-8-azapurine as well. The N7- and N8-ribosides of the 8-azapurines can be analytically useful, as illustrated by N7-β-d-ribosyl-2,6-diamino-8-azapurine, which is a good fluorogenic substrate for mammalian forms of PNP, including human blood PNP, while the N8-riboside is selective to the E. coli enzyme.

Keywords: 8-azapurines; enzymatic ribosylation; fluorescent nucleosides; purine nucleoside phosphorylase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Ribosylation of 8-azaguanine with α-d-ribose-1-phosphate: possible reaction products. The purine numbering is maintained for simplicity. Only the major tautomeric form of 8-azaguanine (N(9)H) is shown.
Figure 2
Figure 2
The HPLC elution profile for the mixture obtained from the ribosylation of 8-azaguanine with α-d-ribose-1-phosphate as a ribose donor, catalyzed by the N243D mutant of the calf PNP. The Kromasil C8 column (5 µm × 250 × 10 mm) was used, and the reaction mixture eluted with water (10 min) followed by 0%–30% methanol gradient. The first peak (~6 min retention time) was identified as unreacted 8-azaguanine.
Figure 3
Figure 3
Fluorescence changes during the incubation of 16 µM N7-ribosyl-8-azaDaPur in 1000-diluted blood in the presence of 25 mM phosphate. Spectra, excited at 300 nm, were recorded every 5 min, and after 60 min an aliquot of the purified calf PNP was added, and fluorescence recorded after next 3 min (dotted line, 5-fold diminished relative to remaining curves). Note that the first (lowest) curve reflects blood fluorescence background, and minimum at 415 nm is due to the re-absorption by hemoglobin.

Similar articles

Cited by

References

    1. Bzowska A., Kulikowska E., Shugar D. Purine nucleoside phosphorylases: Properties, functions, and clinical aspects. Pharmacol. Ther. 2000;88:349–425. doi: 10.1016/S0163-7258(00)00097-8. - DOI - PubMed
    1. Grunebaum E., Cohen A., Roifman C.M. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr. Opin. Allergy Clin. Immunol. 2013;13:630–638. doi: 10.1097/ACI.0000000000000006. - DOI - PubMed
    1. Edwards P.N. A kinetic, modeling and mechanistic re-analysis of thymidine phosphorylase and some related enzymes. J. Enzym. Inhib. Med. Chem. 2006;21:483–499. doi: 10.1080/14756360600721075. - DOI - PubMed
    1. Taylor Ringia E.A., Schramm V.L. Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr. Top. Med. Chem. 2005;5:1237–1258. doi: 10.2174/156802605774463088. - DOI - PubMed
    1. Robak P., Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat. Rev. 2013;39:851–861. doi: 10.1016/j.ctrv.2013.03.006. - DOI - PubMed

Publication types

MeSH terms